Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors
Plummer, R Sanborn, R de Vries, E Lorusso, P Arkenau, H Uboha, N Wydmanski, J Fidler, M Boni, V Garcia-Corbacho, J
Plummer, R
Sanborn, R
de Vries, E
Lorusso, P
Arkenau, H
Uboha, N
Wydmanski, J
Fidler, M
Boni, V
Garcia-Corbacho, J
Citations
Altmetric:
Abstract
Description
Date
2018
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Plummer R, Sanborn RE, de Vries EGE, Lorusso P, Arkenau HT, Uboha N, et al. 436P Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors. Ann Oncol. 2018;29(suppl_8):143.